Arkadios Wealth Advisors Has $697,000 Stock Position in Elanco Animal Health Incorporated $ELAN

Arkadios Wealth Advisors boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 100.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,782 shares of the company’s stock after purchasing an additional 24,504 shares during the period. Arkadios Wealth Advisors’ holdings in Elanco Animal Health were worth $697,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Elanco Animal Health during the first quarter valued at $111,000. Comerica Bank lifted its position in shares of Elanco Animal Health by 46.4% in the first quarter. Comerica Bank now owns 49,680 shares of the company’s stock worth $522,000 after buying an additional 15,754 shares during the last quarter. Equitable Trust Co. lifted its position in shares of Elanco Animal Health by 65.5% in the second quarter. Equitable Trust Co. now owns 248,108 shares of the company’s stock worth $3,543,000 after buying an additional 98,172 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Elanco Animal Health by 14.0% in the first quarter. PNC Financial Services Group Inc. now owns 13,404 shares of the company’s stock worth $141,000 after buying an additional 1,641 shares during the last quarter. Finally, US Bancorp DE lifted its position in shares of Elanco Animal Health by 18.7% in the first quarter. US Bancorp DE now owns 14,906 shares of the company’s stock worth $157,000 after buying an additional 2,346 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analysts Set New Price Targets

ELAN has been the subject of a number of analyst reports. Leerink Partnrs raised Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Elanco Animal Health in a research report on Wednesday, October 8th. Stifel Nicolaus boosted their price target on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Piper Sandler boosted their price target on Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, August 11th. Finally, Leerink Partners raised Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Elanco Animal Health Trading Up 3.5%

Elanco Animal Health stock opened at $22.92 on Tuesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The business’s 50-day simple moving average is $19.89 and its 200-day simple moving average is $15.90. The firm has a market capitalization of $11.38 billion, a PE ratio of 26.65, a PEG ratio of 3.45 and a beta of 1.71. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $22.96.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.